Study identification

EU PAS number

EUPAS39494

Study ID

39495

Official title and acronym

Expert opinion on the impact of inhaler choice on climate change and personalised healthcare

DARWIN EU® study

No

Study countries

Australia
Austria
Belgium
Canada
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Japan
Korea, Republic of
Netherlands
Norway
Portugal
Singapore
Spain
Sweden
Switzerland
United Kingdom
United Kingdom (Northern Ireland)

Study description

This project aims to provide an opinion piece on choice of inhaler delivery method and the impact of on climate change and personalised healthcare. It has the following objectives: 1. Identify experience and preferences of patients and healthcare professionals (HCPs) of inhaler choice/change in relation to climate change and personalized healthcare. 2. Gather expert opinion and consensus on (a) costs to environment (b) impact on personalized healthcare. 3. An extensive literature review covering current discussion on the above topics. This research will offer expert opinion and consensus of physicians and health care workers on: • (a) Costs to environment: The impact of inhaler choice and switching inhaler delivery system on climate change, as well as short-term vs long-term solutions for reduction of impact. The research will also gather information from patients on: • (b) Personal impact: The impact of changing medication that has affected their personalized healthcare plan and inhaler use.

Study status

Finalised
Research institutions and networks

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Omar Usmani

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Boehringer Ingelheim, Chiesi, Kindeva
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable